Merck & Company Inc (MRK)vsNervGen Pharma Corp. (NGEN)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
NGEN
NervGen Pharma Corp.
$3.63
-3.20%
HEALTHCARE · Cap: $311.58M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
NGEN
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for NGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : NGEN
NGEN has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NGEN carries more volatility with a beta of 0.99 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 17/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?